St. Jude Medical EnligHTN III Study Shows Renal Denervation Safe And Effective

(RTTNews) - St. Jude Medical Inc. (STJ) announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure.

The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes through six months of follow-up for 39 eligible patients.

The company noted that preliminary results confirmed safe, rapid and sustained reduction in blood pressure measurements for patients with drug-resistant hypertension, meaning their high blood pressure could not be controlled through medication.

Six-month EnligHTN III data showed: an average systolic blood pressure reduction of 25 mmHg points; 81 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit; No serious device- or procedure-related adverse events reported.